A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease

被引：112

作者：

Hamlin, Clive ^{[1
]}

Puoti, Gianfranco ^{[1
]}

Berri, Sally ^{[1
]}

Sting, Elliott ^{[1
]}

Harris, Carrie ^{[1
]}

Cohen, Mark ^{[1
]}

Spear, Charles ^{[1
]}

Bizzi, Alberto ^{[3
]}

Debanne, Sara M. ^{[2
]}

Rowland, Douglas Y. ^{[2
]}

机构：

[1] Case Western Reserve Univ, Dept Pathol, Natl Prion Dis Pathol Surveillance Ctr, Cleveland, OH 44106 USA

[2] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA

[3] Ist Neurol Carlo Besta, Milan, Italy

来源：

NEUROLOGY | 2012年 / 79卷 / 06期

关键词：

NEURON-SPECIFIC ENOLASE; CEREBROSPINAL-FLUID; ELEVATED LEVELS; BIOMARKERS; 14-3-3-PROTEIN; CLASSIFICATION;

D O I：

10.1212/WNL.0b013e318263565f

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Objective: To compare the respective efficiency of CSF tau (quantitative) and CSF 14-3-3 protein (qualitative) in the diagnosis of prion disease. Methods: We made measurements on 420 live subjects, who subsequently underwent a postmortem neuropathology examination, including protein chemistry, immunohistochemistry, and histology. We performed tau by ELISA. We detected 14-3-3 protein by Western blot. Both assays were optimized for maximum efficiency (accuracy). Results: We found tau and 14-3-3 proteins to be closely correlated, but tau had a significantly better ability to predict disease status than 14-3-3 protein. Also, tau distinguished disease status at least as well as when both assays' results are combined in a variety of ways. Importantly, the area under the receiver operating characteristic curve for tau (0.82) was significantly larger than that for 14-3-3 protein (0.68) (p < 0.001). Diagnostic test statistics are provided for the study subjects with 58.3% prevalence, and for a more typical, nonselected, 7.5% prevalence as received by our center. Conclusion: In this study, tau is superior to 14-3-3 protein as a marker in the diagnosis of Creutzfeldt-Jakob disease, and is as efficient singly compared to a variety of combinations with 14-3-3 protein. This is the first study of this magnitude to examine prion disease diagnostic tests in a carefully characterized patient population with detailed statistical evaluation. Neurology (R) 2012;79:547-552

引用

页码：547 / 552

页数：6

共 28 条

[1] The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer's disease [J].

Bahl, Justyna Maria Czarna ;

Heegaard, Niels H. H. ;

Falkenhorst, Gerhard ;

Laursen, Henning ;

Hogenhaven, Hans ;

Molbak, Kare ;

Jespersgaard, Cathrine ;

Hougs, Lotte ;

Waldemar, Gunhild ;

Johannsen, Peter ;

Christiansen, Michael .

NEUROBIOLOGY OF AGING, 2009, 30 (11) :1834-1841

[2] 14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease [J].

Beaudry, P ;

Cohen, P ;

Brandel, JP ;

Delasnerie-Lauprêtre, N ;

Richard, S ;

Launay, JM ;

Laplanche, JL .

DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 1999, 10 (01) :40-46

[3] Brain-derived proteins in the CSF, do they correlate with brain pathology in CJD? [J].

Boesenberg-Grosse, Constanze ;

Schulz-Schaeffer, Walter J. ;

Bodemer, Monika ;

Ciesielczyk, Barbara ;

Meissner, Bettina ;

Krasnianski, Anna ;

Bartl, Mario ;

Heinemann, Uta ;

Varges, Daniela ;

Eigenbrod, Sabina ;

Kretzschmar, Hans A. ;

Green, Alison ;

Zerr, Inga .

BMC NEUROLOGY, 2006, 6 (1)

[4] Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt-Jakob disease [J].

Chapman, T ;

McKeel, DW ;

Morris, JC .

NEUROLOGY, 2000, 55 (09) :1396-1397

[5] Treatable Neurological Disorders Misdiagnosed as Creutzfeldt-Jakob Disease [J].

Chitravas, Numthip ;

Jung, Richard S. ;

Kofskey, Diane M. ;

Blevins, Janis E. ;

Gambetti, Pierluigi ;

Leigh, R. John ;

Cohen, Mark L. .

ANNALS OF NEUROLOGY, 2011, 70 (03) :437-444

[6] Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease [J].

Collins, S. J. ;

Sanchez-Juan, P. ;

Masters, C. L. ;

Klug, G. M. ;

van Duijn, C. ;

Poleggi, A. ;

Pocchiari, M. ;

Almonti, S. ;

Cuadrado-Corrales, N. ;

de Pedro-Cuesta, J. ;

Budka, H. ;

Gelpi, E. ;

Glatzel, M. ;

Tolnay, M. ;

Hewer, E. ;

Zerr, I. ;

Heinemann, U. ;

Kretszchmar, H. A. ;

Jansen, G. H. ;

Olsen, E. ;

Mitrova, E. ;

Alperovitch, A. ;

Brandel, J. -P. ;

Mackenzie, J. ;

Murray, K. ;

Will, R. G. .

BRAIN, 2006, 129 :2278-2287

[7] Sporadic and familial CJD: classification and characterisation [J].

Gambetti, P ;

Kong, QZ ;

Zou, WQ ;

Parchi, P ;

Chen, SG .

BRITISH MEDICAL BULLETIN, 2003, 66 :213-+

[8] Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease [J].

Geschwind, MD ;

Martindale, J ;

Miller, D ;

DeArmond, SJ ;

Uyehara-Lock, J ;

Gaskin, D ;

Kramer, JH ;

Barbaro, NM ;

Miller, BL .

ARCHIVES OF NEUROLOGY, 2003, 60 (06) :813-816

[9] 14-3-3 CSF levels in sporadic Creutzfeldt-Jakob disease differ across molecular subtypes [J].

Gmitterova, K. ;

Heinemann, U. ;

Bodemer, M. ;

Krasnianski, A. ;

Meissner, B. ;

Kretzschmar, H. A. ;

Zerr, I. .

NEUROBIOLOGY OF AGING, 2009, 30 (11) :1842-1850

[10] Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives [J].

Hampel, Harald ;

Frank, Richard ;

Broich, Karl ;

Teipel, Stefan J. ;

Katz, Russell G. ;

Hardy, John ;

Herholz, Karl ;

Bokde, Arun L. W. ;

Jessen, Frank ;

Hoessler, Yvonne C. ;

Sanhai, Wendy R. ;

Zetterberg, Henrik ;

Woodcock, Janet ;

Blennow, Kaj .

NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (07) :560-574

← 1 2 3 →